Swarm of ‘defensive' bees spotted in Alabama, officials say. How to stay safe
The bees were found in Barbour County and humanely euthanized to protect the state's other honeybee populations, the Alabama Department of Agriculture and Industries said in a June 30 news release.
'There is no reason for public concern at this time, but we are treating this situation seriously,' Commissioner of Agriculture & Industries Rick Pate said in the release. 'Our team is actively collaborating with local beekeepers and entomology experts to ensure swift detection and appropriate response.'
Officials said they put traps within a five-mile radius of where the bees were originally found to further monitor bee populations.
Barbour County borders Georgia and is about an 80-mile drive southeast from Montgomery.
What are Africanized honeybees?
A crossbreed of African and European honeybees, Africanized honeybees are known for their 'more defensive behavior,' according to the Alabama Department of Agriculture and Industries.
These types of bees swarm more often, nest in more locations and respond in higher numbers when provoked, officials said.
'If I'm working around one of my European honey bee colonies and I knock on it with a hammer, it might send out five to 10 individuals to see what's going on. They would follow me perhaps as far as my house and I might get stung once,' Jamie Ellis, a professor of honey bee research at the University of Florida, told USA Today.
With an Africanized colony, however, 50 to 100 individuals would be sent out in response to the same thing, and they'd follow him further and sting him more, Ellis told the outlet.
An encounter with a swarm of Africanized honeybees can produce more stings, making them more deadly in some cases, according to experts.
Between 2011 and 2021, an average of 72 deaths per year came from hornets, wasps and bee stings, according to the latest data from the Centers for Disease Control and Prevention.
What to do if you encounter an Africanized honeybee
According to guidance from the Alabama Department of Agriculture and Industries and The University of Florida, if you see a bee or a swarm you should:
Stay away. Don't bother or remove bee colonies or swarms.Report any 'aggressive bee behavior' to officials. Don't swat at the bees.Leave the area right away. 'Cover your nose and mouth with your shirt.' Seek shelter in a building or vehicle.Don't go near a victim to help, stand away and tell them to leave.
What to do if you're stung by a bee
The University of Florida advises a person do the following if they are stung by a bee:
Scrape the stingers out with a blunt object, like a fingernail or credit card.Wash the sting with soap and water.Ice the sting to stop the swelling.Watch for signs of allergic reaction, including hives, difficulty breathing and dizziness.If you have an allergic reaction, contact emergency personnel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
an hour ago
The US plans to begin breeding billions of flies to fight a pest
TOPEKA, Kan. -- The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot. That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before. 'It's an exceptionally good technology,' said Edwin Burgess, an assistant professor at the University of Florida who studies parasites in animals, particularly livestock. 'It's an all-time great in terms of translating science to solve some kind of large problem.' The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies — sterilizing them with radiation before releasing them — so they can mate ineffectively with females and over time cause the population to die out. It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year. The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary. Most fly larvae feed on dead flesh, making the New World screwworm fly and its Old World counterpart in Asia and Africa outliers — and for the American beef industry, a serious threat. Females lay their eggs in wounds and, sometimes, exposed mucus. 'A thousand-pound bovine can be dead from this in two weeks,' said Michael Bailey, president elect of the American Veterinary Medicine Association. Veterinarians have effective treatments for infested animals, but an infestation can still be unpleasant — and cripple an animal with pain. Don Hineman, a retired western Kansas rancher, recalled infected cattle as a youngster on his family's farm. 'It smelled nasty,' he said. 'Like rotting meat.' The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA. The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating. One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives. Alarmed about the fly's migration north, the U.S. temporarily closed its southern border in May to imports of live cattle, horses and bison and it won't be fully open again at least until mid-September. But female flies can lay their eggs in wounds on any warm-blooded animal, and that includes humans. Decades ago, the U.S. had fly factories in Florida and Texas, but they closed as the pest was eradicated. The Panama fly factory can breed up to 117 million a week, but the USDA wants the capacity to breed at least 400 million a week. It plans to spend $8.5 million on the Texas site and $21 million to convert a facility in southern Mexico for breeding sterile fruit flies into one for screwworm flies. In one sense, raising a large colony of flies is relatively easy, said Cassandra Olds, an assistant professor of entomology at Kansas State University. But, she added, 'You've got to give the female the cues that she needs to lay her eggs, and then the larvae have to have enough nutrients." Fly factories once fed larvae horse meat and honey and then moved to a mix of dried eggs and either honey or molasses, according to past USDA research. Later, the Panama factory used a mix that included egg powder and red blood cells and plasma from cattle. In the wild, larvae ready for the equivalent of a butterfly's cocoon stage drop off their hosts and onto the ground, burrow just below the surface and grow to adulthood inside a protective casing making them resemble a dark brown Tic Tac mint. In the Panama factory, workers drop them into trays of sawdust. Security is an issue. Sonja Swiger, an entomologist with Texas A&M University's Extension Service, said a breeding facility must prevent any fertile adults kept for breeding stock from escaping. Dropping flies from the air can be dangerous. Last month, a plane freeing sterile flies crashed near Mexico's border with Guatemala, killing three people. In test runs in the 1950s, according to the USDA, scientists put the flies in paper cups and then dropped the cups out of planes using special chutes. Later, they loaded them into boxes with a machine known as a 'Whiz Packer.' The method is still much the same: Light planes with crates of flies drop those crates. Burgess called the development of sterile fly breeding and distribution in the 1950s and 1960s one of the USDA's 'crowning achievements.' Some agriculture officials argue now that new factories shouldn't be shuttered after another successful fight. 'Something we think we have complete control over — and we have declared a triumph and victory over — can always rear its ugly head again,' Burgess said.
Miami Herald
2 hours ago
- Miami Herald
Overnight Canaveral launch marked 500th for SpaceX Falcon 9
An early Wednesday morning launch on the Space Coast marked the 500th time SpaceX has flown its workhorse Falcon 9 rocket, reusing the fleet-leading first stage booster for a record 29th time. The latest flight with a payload of 27 Starlink satellites lifted off Cape Canaveral Space Force Station's Space Launch Complex 40 at 2:28 a.m. coming just over nine hours since launch No. 499 from neighboring Kennedy Space Center, which sent up a European weather satellite. The booster, which first flew in 2021 and had since been used on two human spaceflights among 28 previous missions, completed flight 29 landing downrange on the droneship A Shortfall of Gravitas. The first Falcon 9 launched in 2010, and only two of the 500 launches have ended in complete failure. Elon Musk's company had its first successful orbital launch with the Falcon 1 rocket in 2008, but it only flew one more time before switching to the Falcon 9. It also has flown the Falcon Heavy, which is essentially three Falcon 9 rockets strapped together, 11 times. The launch was the 83rd Falcon 9 mission for SpaceX in 2025 from all of its facilities in Florida and California. No Falcon Heavy has launched yet this year. For the Space Coast, it marked the 58th orbital mission, with all by three flown by SpaceX. ------------ Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Business Wire
3 hours ago
- Business Wire
Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. 'We are pleased to report that the European regulatory review for INTERCEPT RBC is advancing ahead of plan and that TÜV-SÜD, our Notified Body, has completed their review of the clinical module and transferred information to the State Institute for Drug Control (SÚKL) in the Czech Republic, for consultation. Reaching this meaningful milestone enables SÚKL to initiate its review of the active pharmaceutical ingredient (API) module. In addition, as we had anticipated, SÚKL has agreed to review our submission as the Competent Authority,' said William 'Obi' Greenman, Cerus' president and chief executive officer. 'We are looking forward to working collaboratively with both TÜV-SÜD and SÚKL to facilitate the completion of the review process for our enhanced CE Mark submission for the INTERCEPT RBC system.' Importantly, the clinical module that has now been successfully reviewed by TÜV-SÜD included the positive results from the U.S. Phase 3 ReCePI clinical trial, expanding Cerus' CE Mark submission to cover all patient indications for RBC transfusion. SÚKL will now review the API module in the application, before the submission goes back to TÜV-SÜD for completion of manufacturing facility audits and certification prior to CE Mark decision. Under the European Medical Device Regulation (MDR), the CE Mark submission review process for Class III devices such as the INTERCEPT RBC system is rigorous and involves both Notified Bodies and Competent Authorities. The Notified Body evaluates multiple aspects including the manufacturer's quality system and technical documentation to ensure adherence to European regulations. The Competent Authority is responsible for reviewing the active pharmaceutical ingredient manufacturing and safety. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Forward-Looking Statements Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus' INTERCEPT RBC programs and prospects, including statements relating to the anticipated completion of Cerus' CE Mark application review process for the INTERCEPT RBC system and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: the uncertain and time-consuming development and regulatory process, including the risks that (a) Cerus' submission to SÚKL may not satisfactorily address the issues in its prior submission that prevented CE Mark approval for the INTERCEPT RBC system, (b) Cerus may be unable to meet the additional applicable requirements to complete the CE Mark application review process for INTERCEPT RBCs in a timely manner or at all, and that Cerus may otherwise determine to substantially delay or abandon its efforts to seek CE Mark approval of the INTERCEPT RBC system, and (c) Cerus may otherwise be unable to obtain any regulatory approvals of the INTERCEPT RBC system in a timely manner or at all; Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risk that Cerus may be required to engage and validate a new supplier for key components of the INTERCEPT RBC system, which would substantially delay the CE Mark application review process for INTERCEPT RBCs and/or a review decision thereon; commercialization and market acceptance of, and customer demand for, the INTERCEPT RBC system, if approved; successfully launching a new commercial product; Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System, including the INTERCEPT RBC system, is safe, effective and economical; future opportunities and plans, including the uncertainty of Cerus' future capital requirements and the sufficiency of its cash resources and anticipated funding under its agreements with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response; as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' in Cerus' Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 1, 2025. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.
